Significance of pathomorphological findings of primary prostate biopsy and modern biomarkers in risk stratification of clinically significant prostate cancer in patients with PI-RADS 3
Science and Innovations in Medicine · 2026-10-07 · 11 (4) · 287-292
DOI: 10.35693/sim706757 ↗At a glance
Journal article in Science and Innovations in Medicine, published online on 2026-10-07. Written by Vitalii G. Lyubov and 1 co-authors. 15 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Aim: to evaluate the prognostic value of pathomorphological findings of primary prostate biopsy (ASAP, atypical small acinar proliferation, multifocal HGPIN, high-grade prostatic intraepithelial neoplasia) and modern biomarkers (PHI, Prostate Health Index, 4Kscore test) in patients with equivocal multiparametric MRI results (PI-RADS 3) and persistent elevation of prostate-specific antigen after negative primary biopsy. Material and methods. This retrospective cohort study included 216 patients observed at the Republican Clinical Oncology Dispensary named after Professor M.Z. Sigal from 2018 to 2024. All patients underwent primary prostate biopsy that did not reveal adenocarcinoma, and subsequently repeated biopsy (MRIultrasound fusion) due to persistent total PSA ≥ 4.0 ng/mL. Three predictive models were constructed using logistic regression: basic (clinical laboratory and MR parameters), extended (basic + ASAP and multifocal HGPIN), and full (extended + PHI, 4Kscore). Discriminative ability was assessed by the area under the ROC curve (AUC), and clinical utility by calculating the number of repeat biopsies needed to detect one csPCa case (Number Needed to Biopsy, NNB).
Results
The detection rate of csPCa in the study subgroup was 18.5% (40/216). The full model demonstrated the best discriminative ability (AUC 0.87; 95% CI 0.82–0.91) compared to the basic (AUC 0.73) and extended (AUC 0.80) models. Applying the full model at a predicted probability threshold 30% would reduce the number of repeat biopsies by 33.8% (73 of 216) while missing only one csPCa case (ISUP 2). In the group with a calculated risk ≤ 30%, the NNB was 22 vs. 5.4 in the overall cohort.
Conclusion
Integration of pathomorphological findings from primary prostate biopsy and modern biomarkers into a multifactorial predictive model significantly improves risk stratification for csPCa in patients with PI-RADS 3 and a negative primary biopsy.
Cite
APA
Lyubov, V. G., & Gataullin, I. G. (2026). Significance of pathomorphological findings of primary prostate biopsy and modern biomarkers in risk stratification of clinically significant prostate cancer in patients with PI-RADS 3. Science and Innovations in Medicine, 11(4), 287-292. https://doi.org/10.35693/sim706757
Vancouver
Lyubov VG, Gataullin IG. Significance of pathomorphological findings of primary prostate biopsy and modern biomarkers in risk stratification of clinically significant prostate cancer in patients with PI-RADS 3. Science and Innovations in Medicine. 2026;11(4):287-292. doi:10.35693/sim706757
BibTeX
@article{Lyubov2026,
author = {Lyubov, Vitalii G. and Gataullin, Ilgiz G.},
title = {Significance of pathomorphological findings of primary prostate biopsy and modern biomarkers in risk stratification of clinically significant prostate cancer in patients with PI-RADS 3},
journal = {Science and Innovations in Medicine},
year = {2026},
volume = {11},
number = {4},
pages = {287--292},
doi = {10.35693/sim706757}
}
EUVIMED